We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+30.48%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$621M
AUM Growth
+$72.3M
Cap. Flow
-$24.9M
Cap. Flow %
-4%
Top 10 Hldgs %
33.04%
Holding
112
New
30
Increased
19
Reduced
32
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.5M
2
NVMI
Nova
NVMI
+$15.3M
3
GLBE icon
Global E Online
GLBE
+$9.72M
4
TBLA icon
Taboola.com
TBLA
+$6.52M
5
META icon
Meta Platforms (Facebook)
META
+$6.21M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.82M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.35M
3
AMZN icon
Amazon
AMZN
+$5.55M
4
IRON icon
Disc Medicine
IRON
+$5.23M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$4.67M

Sector Composition

Rank Sector Weight
1 Healthcare 63.14%
2 Technology 15.8%
3 Communication Services 3.76%
4 Consumer Discretionary 3.08%
5 Utilities 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
76
Rigel Pharmaceuticals
RIGL
$681M
$1.78M 0.29%
122,813
– –
CRGX
77
DELISTED
CARGO Therapeutics
CRGX
$1.74M 0.28%
+75,000
New +$1.27M
GILD icon
78
Gilead Sciences
GILD
$162B
$1.62M 0.26%
20,000
-20,000
-50% -$1.56M
COGT icon
79
Cogent Biosciences
COGT
$6.65B
$1.52M 0.25%
259,201
-160,799
-38% -$1.23M
CGEN icon
80
Compugen
CGEN
$222M
$1.52M 0.25%
769,239
-550,000
-42% -$480K
AMLX icon
81
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
$1.47M 0.24%
+100,000
New +$1.53M
GOSS icon
82
Gossamer Bio
GOSS
$82.9M
$1.22M 0.2%
1,338,090
-594,478
-31% -$439K
SRPT icon
83
Sarepta Therapeutics
SRPT
$1.57B
$1.21M 0.19%
12,500
-37,500
-75% -$3.6M
FIVN icon
84
FIVE9
FIVN
$2.11B
$1.18M 0.19%
+15,000
New +$1.04M
ORIC icon
85
Oric Pharmaceuticals
ORIC
$1.15B
$1.17M 0.19%
+126,800
New +$917K
RZLT icon
86
Rezolute
RZLT
$454M
$989K 0.16%
996,710
– –
APGE icon
87
Apogee Therapeutics
APGE
$10.1B
$838K 0.13%
30,000
– –
PRME icon
88
Prime Medicine
PRME
$527M
$655K 0.11%
+73,980
New +$570K
RNAC icon
89
Cartesian Therapeutics
RNAC
$229M
$519K 0.08%
25,071
– –
MDWD icon
90
MediWound
MDWD
$181M
$498K 0.08%
48,980
-59,553
-55% -$535K
ELEV
91
DELISTED
Elevation Oncology
ELEV
$483K 0.08%
900,000
– –
VTYX
92
DELISTED
Ventyx Biosciences
VTYX
$445K 0.07%
+180,000
New +$1.71M
MORF
93
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$432K 0.07%
14,952
-75,048
-83% -$1.79M
IMTXW
94
DELISTED
Immatics N.V. Warrants
IMTXW
$292K 0.05%
100,000
– –
GLUE icon
95
Monte Rosa Therapeutics
GLUE
$1.4B
$274K 0.04%
+48,511
New +$190K
REPL icon
96
Replimune Group
REPL
$941M
$136K 0.02%
16,096
-168,920
-91% -$1.96M
FRLN
97
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$105K 0.02%
+16,445
New +$88.1K
ARBE icon
98
Arbe Robotics
ARBE
$80.3M
$94.1K 0.02%
+43,165
New +$87.4K
CATX icon
99
Perspective Therapeutics
CATX
$332M
$10.3K ﹤0.01%
+2,567
New +$7.23K
CRWD icon
100
CrowdStrike
CRWD
$194B
– –
-60,000
Closed -$2.51M
1 2 3
4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2023 Portfolio in Review

As of Q4 2023, Sphera Funds Management held 112 positions worth $621M, up 13% from $549M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management withdrew a net $24.9M in Q4 2023, closing 13 positions and reducing 32 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $6.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 61% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in Nova worth $18.1M.

  • Sphera Funds Management's largest Q4 2023 buy was Nova: 132,000 shares worth $18.1M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q4 2023, an estimated $17.5M increase.
  • Sphera Funds Management's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $6.82M.
  • Sphera Funds Management fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $6.35M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $621M portfolio in Q4 2023.
  • Sphera Funds Management opened 30 new positions and closed 13 in Q4 2023.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $621M.

Based on Sphera Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.